4-Methylthioamphetamine Increases Dopamine in the Rat Striatum and has Rewarding Effects In Vivo

Basic and Clinical Pharmacology and Toxicology

Volumn 111, Issue 6, 2012, Pages 371-379

  Sotomayor Zárate, Ramón ^a,b   Quiroz, Gabriel ^a   Araya, Katherine A ^a   Abarca, Jorge ^a   Ibáñez, María R ^a   Montecinos, Alejandro ^c   Guajardo, Carlos ^c   Núñez, Gabriel ^c   Fierro, Angélica ^c,d   Moya, Pablo R ^e   Iturriaga Vásquez, Patricio ^d,f   Gómez Molina, Cristóbal ^f   Gysling, Katia ^a   Reyes Parada, Miguel ^c,d,g  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b UNIVERSIDAD DE VALPARAÍSO   (Chile)

^c UNIVERSIDAD DE SANTIAGO DE CHILE   (Chile)

^d Iniciativa Cientifica Milenio Santiago   (Chile)

^e NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^f UNIVERSITY OF CHILE   (Chile)

^g UNIVERSIDAD AUTÓNOMA DE CHILE   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

4 METHYLTHIOAMPHETAMINE; AMPHETAMINE DERIVATIVE; DOPAMINE; DOPAMINE TRANSPORTER; PROTEIN C FOS; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOSE RESPONSE; DRUG PROTEIN BINDING; EXTRACELLULAR SPACE; IN VITRO STUDY; IN VIVO STUDY; LOCOMOTION; MALE; MOLECULAR DOCKING; NONHUMAN; NUCLEUS ACCUMBENS; PLACE PREFERENCE; PRIORITY JOURNAL; RADIOASSAY; RAT; REWARD; STRUCTURAL HOMOLOGY;

AMPHETAMINES; ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORPUS STRIATUM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; MALE; MOTOR ACTIVITY; NUCLEUS ACCUMBENS; RATS; RATS, SPRAGUE-DAWLEY;

RATTUS;

EID: 84869202147     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2012.00926.x     Document Type: Article

References (52)

1. Holland GF, Buck CJ, Weissman A. Anorexigenic agents: aromatic substituted 1-phenyl-2-propylamines. J Med Chem 1963;6:519-24.
2. Huang X, Marona-Lewicka D, Nichols DE. p-Methylthioamphetamine is a potent new non-neurotoxic serotonin-releasing agent. Eur J Pharmacol 1992;229:31-8.
3. Nichols DE, Marona-Lewicka D, Huang X, Johnson MP. Novel serotonergic agents. Drug Des Discov 1993;9:299-312.
4. Scorza C, Silveira R, Nichols DE, Reyes-Parada M. Effects of 5-HT-releasing agents on the extracellullar hippocampal 5-HT of rats. Implications for the development of novel antidepressants with a short onset of action. Neuropharmacology 1999;38:1055-61.
5. Gobbi M, Moia M, Pirona L, Ceglia I, Reyes-Parada M, Scorza C et al. p-Methylthioamphetamine and 1-(m-chlorophenyl)piperazine, two non-neurotoxic 5-HT releasers in vivo, differ from neurotoxic amphetamine derivatives in their mode of action at 5-HT nerve endings in vitro. J Neurochem 2002;82:1435-43.
6. Murphy J, Flynn JJ, Cannon DM, Guiry PJ, McCormack P, Baird AW et al. In vitro neuronal and vascular responses to 5-hydroxytryptamine: modulation by 4-methylthioamphetamine, 4-methylthiomethamphetamine and 3, 4-methylenedioxymethamphetamine. Eur J Pharmacol 2002;444:61-7.
7. EMCDDA. Report on the Risk Assessment of 4-MTA in the Framework of the Joint Action on New Synthetic Drugs. Office for Official Publications of the European Communities, Luxembourg, 1999;3-114.
8. Elliott SP. Fatal poisoning with a new phenylethylamine: 4-methylthioamphetamine (4-MTA). J Anal Toxicol 2000;24:85-9.
9. De Letter EA, Coopman VA, Cordonnier JA, Piette MH. One fatal and seven non-fatal cases of 4-methylthioamphetamine (4-MTA) intoxication: clinico-pathological findings. Int J Legal Med 2001;114:352-6.
10. Nichols DE. Legal highs: the dark side of medicinal chemistry. Nature 2011;469:7.
11. Scorza MC, Carrau C, Silveira R, Zapata-Torres G, Cassels BK, Reyes-Parada M. Monoamine oxidase inhibitory properties of some methoxylated and alkylthio amphetamine derivatives: structure-activity relationships. Biochem Pharmacol 1997;54:1361-9.
12. Carmo H, Remiao F, Carvalho F, Fernandes E, de Boer D, dos Reys LA et al. 4-Methylthioamphetamine-induced hyperthermia in mice: influence of serotonergic and catecholaminergic pathways. Toxicol Appl Pharmacol 2003;190:262-71.
13. Quinn ST, Guiry PJ, Schwab T, Keenan AK, McBean GJ. Blockade of noradrenaline transport abolishes 4-methylthioamphetamine-induced contraction of the rat aorta in vitro. Auton Autacoid Pharmacol 2006;26:335-44.
14. Decaestecker T, De Letter E, Clauwaert K, Bouche MP, Lambert W, Van Bocxlaer J et al. Fatal 4-MTA intoxication: development of a liquid chromatographic-tandem mass spectrometric assay for multiple matrices. J Anal Toxicol 2001;25:705-10.
15. Marona-Lewicka D, Nichols DE. The effect of selective serotonin releasing agents in the chronic mild stress model of depression in rats. Stress 1997;2:91-100.
16. Cloonan SM, Keating JJ, Butler SG, Knox AJ, Jorgensen AM, Peters GH et al. Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem 2009;44:4862-88.
17. Hurtado-Guzmán C, Fierro A, Iturriaga-Vasquez P, Sepulveda-Boza S, Cassels BK, Reyes-Parada M. Monoamine oxidase inhibitory properties of optical isomers and N-substituted derivatives of 4-methylthioamphetamine. J Enzyme Inhib Med Chem 2003;18:339-47.
18. Boja JW, Rahman MA, Philip A, Lewin AH, Carroll FI, Kuhar MJ. Isothiocyanate derivatives of cocaine: irreversible inhibition of ligand binding at the dopamine transporter. Mol Pharmacol 1991;39:339-45.
19. Carroll FI, Gray JL, Abraham P, Kuzemko MA, Lewin AH, Boja JW et al. 3-Aryl-2-(3′-substituted-1′, 2′, 4′-oxadiazol-5′-yl)tropane analogues of cocaine: affinities at the cocaine binding site at the dopamine, serotonin, and norepinephrine transporters. J Med Chem 1993;36:2886-90.
20. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI et al. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 2001;39:32-41.
21. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates, 2nd edn. Academic Press, Sydney, NSW, 1986.
22. Sotomayor-Zarate R, Araya KA, Pereira P, Blanco E, Quiroz G, Pozo S et al. Activation of GABA-B receptors induced by systemic amphetamine abolishes dopamine release in the rat lateral septum. J Neurochem 2010;114:1678-86.
23. Sotomayor R, Forray MI, Gysling K. Acute morphine administration increases extracellular DA levels in the rat lateral septum by decreasing the GABAergic inhibitory tone in the ventral tegmental area. J Neurosci Res 2005;81:132-9.
24. Fuentealba JA, Gysling K, Andres ME. Increased locomotor response to amphetamine induced by the repeated administration of the selective kappa-opioid receptor agonist U-69593. Synapse 2007;61:771-7.
25. Yamashita A, Singh SK, Kawate T, Jin Y, Gouaux E. Crystal structure of a bacterial homologue of Na+/Cl-dependent neurotransmitter transporters. Nature 2005;437:215-23.
26. Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 1993;234:779-815.
27. Gordon JC, Myers JB, Folta T, Shoja V, Heath LS, Onufriev A. H++: a server for estimating pKas and adding missing hydrogens to macromolecules. Nucleic Acids Res 2005;33:W368-71.
28. Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, Villa E et al. Scalable molecular dynamics with NAMD. J Comput Chem 2005;26:1781-802.
29. Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol Graph 1996;14:33-8.
30. Wiederstein M, Sippl MJ. ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Res 2007;35:W407-10.
31. Melo F, Devos D, Depiereux E, Feytmans E. ANOLEA: a www server to assess protein structures. Proc Int Conf Intell Syst Mol Biol 1997;5:187-90.
32. Laskowski RA, MacArthur MW, Moss DS, Thornton JM. PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Crystallogr 1993;26:283-91.
33. Abagyan RA, Totrov MM, Kuznetsov DA. ICM: a new method for protein modeling and design: applications to docking and structure prediction from the distorted native conformation. J Comp Chem 1994;15:488-506.
34. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK et al. Automated docking using a lamarckian genetic algorithm and empirical binding free energy function. J Comput Chem 1998;19:1639-62.
35. Volz TJ, Hanson GR, Fleckenstein AE. The role of the plasmalemmal dopamine and vesicular monoamine transporters in methamphetamine-induced dopaminergic deficits. J Neurochem 2007;101:883-8.
36. Indarte M, Madura JD, Surratt CK. Dopamine transporter comparative molecular modeling and binding site prediction using the LeuT(Aa) leucine transporter as a template. Proteins 2008;70:1033-46.
37. Singh SK, Yamashita A, Gouaux E. Antidepressant binding site in a bacterial homologue of neurotransmitter transporters. Nature 2007;448:952-6.
38. Zhou Z, Zhen J, Karpowich NK, Goetz RM, Law CJ, Reith ME et al. LeuT-desipramine structure reveals how antidepressants block neurotransmitter reuptake. Science 2007;317:1390-3.
39. Quick M, Winther AM, Shi L, Nissen P, Weinstein H, Javitch JA. Binding of an octylglucoside detergent molecule in the second substrate (S2) site of LeuT establishes an inhibitor-bound conformation. Proc Natl Acad Sci USA 2009;106:5563-8.
40. de Boer D, Egberts T, Maes RA. Para-methylthioamphetamine, a new amphetamine designer drug of abuse. Pharm World Sci 1999;21:47-8.
41. Poortman AJ, Lock E. Analytical profile of 4-methylthioamphetamine (4-MTA), a new street drug. Forensic Sci Int 1999;100:221-33.
42. Winstock AR, Wolff K, Ramsey J. 4-MTA: a new synthetic drug on the dance scene. Drug Alcohol Depend 2002;67:111-5.
43. Elliott SP. Analysis of 4-methylthioamphetamine in clinical specimens. Ann Clin Biochem 2001;38:339-47.
44. Gobbi M, Funicello M, Gerstbrein K, Holy M, Moya PR, Sotomayor R et al. N, N-dimethyl-thioamphetamine and methyl-thioamphetamine, two non-neurotoxic substrates of 5-HT transporters, have scant in vitro efficacy for the induction of transporter-mediated 5-HT release and currents. J Neurochem 2008;105:1770-80.
45. Nash JF. Ketanserin pretreatment attenuates MDMA-induced dopamine release in the striatum as measured by in vivo microdialysis. Life Sci 1990;47:2401-8.
46. Gudelsky GA, Yamamoto BK, Nash JF. Potentiation of 3, 4-methylenedioxymethamphetamine-induced dopamine release and serotonin neurotoxicity by 5-HT2 receptor agonists. Eur J Pharmacol 1994;264:325-30.
47. Shi L, Quick M, Zhao Y, Weinstein H, Javitch JA. The mechanism of a neurotransmitter:sodium symporter-inward release of Na+ and substrate is triggered by substrate in a second binding site. Mol Cell 2008;30:667-77.
48. Schmitt KC, Mamidyala S, Biswas S, Dutta AK, Reith ME. Bivalent phenethylamines as novel dopamine transporter inhibitors: evidence for multiple substrate-binding sites in a single transporter. J Neurochem 2010;112:1605-18.
49. Shan J, Javitch JA, Shi L, Weinstein H. The substrate-driven transition to an inward-facing conformation in the functional mechanism of the dopamine transporter. PLoS One 2011;6:e16350.
50. Volz TJ, Schenk JO. A comprehensive atlas of the topography of functional groups of the dopamine transporter. Synapse 2005;58: 72-94.
51. Beuming T, Kniazeff J, Bergmann ML, Shi L, Gracia L, Raniszewska K et al. The binding sites for cocaine and dopamine in the dopamine transporter overlap. Nat Neurosci 2008;11:780-9.
52. Heal DJ, Cheetham SC, Smith SL. The neuropharmacology of ADHD drugs in vivo: insights on efficacy and safety. Neuropharmacology 2009;57:608-18.